Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

Core Viewpoint - Alvotech has successfully completed its offering of Swedish Depository Receipts (SDRs) and is now listed on Nasdaq Stockholm, which is expected to enhance its visibility and access to capital in the Nordic and European markets [2][4][6]. Offering Details - The offering was oversubscribed multiple times, with a total of 441,600 SDRs issued at a price of SEK 87.51, resulting in gross proceeds of approximately SEK 39 million [8]. - The application period for the offering was from May 9 to May 16, 2025, and trading commenced on May 19, 2025, under the ticker "ALVO SDB" [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities by acquiring Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [5]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [5]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve access to regional capital and attract a broader base of institutional and retail investors [6]. - Alvotech is focused on becoming a global leader in biosimilars, with a current pipeline that includes nine disclosed biosimilar candidates targeting various diseases [11]. Shareholder Engagement - The company will offer a free conversion period for existing shareholders to convert their shares into SDRs, with Alvotech covering the conversion fees for one year [9].